
Sign up to save your podcasts
Or


When the FDA approved an RSV vaccine for infants in July of 2023, parents and pediatricians rejoiced. But product shortages and a patchwork of insurance coverage throttled the rollout, leaving many babies still unprotected this winter. Pediatrician and Internist Dr. Wendie Grader-Beck talks with Dr. Josh Sharfstein about her frustrations around implementation, and what needs to be done before the next RSV season for this lifesaving technology to fulfill its promise.
By The Johns Hopkins Bloomberg School of Public Health4.6
618618 ratings
When the FDA approved an RSV vaccine for infants in July of 2023, parents and pediatricians rejoiced. But product shortages and a patchwork of insurance coverage throttled the rollout, leaving many babies still unprotected this winter. Pediatrician and Internist Dr. Wendie Grader-Beck talks with Dr. Josh Sharfstein about her frustrations around implementation, and what needs to be done before the next RSV season for this lifesaving technology to fulfill its promise.

43,543 Listeners

40 Listeners

5 Listeners

27 Listeners

5 Listeners

262 Listeners

56,509 Listeners

494 Listeners

9 Listeners

45 Listeners

92 Listeners

16,353 Listeners

16 Listeners

4,753 Listeners

2 Listeners

4,486 Listeners

391 Listeners

6,552 Listeners

25 Listeners

6,384 Listeners

237 Listeners

65 Listeners

164 Listeners

98 Listeners